Journal
BRITISH JOURNAL OF CANCER
Volume 101, Issue 11, Pages 1807-1812Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/sj.bjc.6605349
Keywords
antibody; Fc receptor; ADCC; fucose
Categories
Ask authors/readers for more resources
A number of antibody products have now become accepted as effective anti-cancer therapies. Despite being mainly designed to act by inhibiting functional tumour antigens, there is increasing evidence that Fc-mediated engagement of the immune system is an important contributor to the efficacy of several of these therapies. The optimisation of this engagement offers the potential not only to augment efficacy against existing targets, but also to exploit non-functional tumour antigens. Antibodies that achieve efficacy wholly or predominantly through Fc-mediated mechanisms, represent rich opportunities for future therapeutics in oncology. This mini review summarises some of the key challenges, which need to be addressed to select the most effective molecules. These include the identification of optimal antibody characteristics and improvement of the drug discovery process, in particular, the relevance and predictive power of existing in vitro and in vivo screening methods. Advances in our understanding of tumour immunobiology and successful application of technologies designed to enhance immune system engagement will further aid this process. British Journal of Cancer (2009) 101, 1807-1812. doi:10.1038/sj.bjc.6605349 www.bjcancer.com Published online 6 October 2009 (C) 2009 Cancer Research UK
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available